Sarcopenia, a progressive skeletal muscle disorder characterized by the loss of muscle mass and function, is becoming a critical public health concern as global life expectancy increases. With the aging population rising rapidly across the globe, the medical need to address sarcopenia is more urgent than ever. This condition not only compromises mobility and quality of life in elderly patients but also significantly increases the risk of falls, hospitalizations, and mortality.
According to Expert Market Research, the sarcopenia market size is expected to grow at a CAGR of 4.30% during the forecast period of 2025–2034. The market is fueled by increasing awareness, new therapeutic developments, and extensive research activities aimed at reducing the burden of sarcopenia, especially across the 8 major markets (United States, EU-4, UK, Japan, China, and others).
Sarcopenia Market Size
The expanding global elderly population is a primary driver of the sarcopenia market’s size and growth. In 2024, populations aged 65 and older surpassed 10% in most developed nations, and by 2050, this demographic is expected to reach nearly 16% globally. This demographic trend directly increases the at-risk population for sarcopenia, prompting growing demand for nutritional, pharmaceutical, and rehabilitative solutions.
Additionally, improved diagnostic protocols and the classification of sarcopenia as a distinct condition by global health organizations have significantly contributed to market expansion. With increased clinical attention and broader insurance coverage in some regions, more patients are receiving targeted treatment.
Sarcopenia Market Share
The sarcopenia market exhibits a varied distribution of market share based on regional healthcare infrastructure, research investments, and access to diagnostic and treatment facilities. High-income countries, especially in North America and Western Europe, currently hold the largest market shares due to advanced medical research capabilities and heightened awareness.
Among the leading segments, protein supplements and pharmacotherapy treatments dominate due to their direct impact on improving muscle mass and function. Meanwhile, oral administration remains the most preferred route, accounting for a significant portion of overall treatment adoption due to ease of use in older adults.
Major market players with dominant shares include:
- Amgen Inc.
- F. Hoffmann-La Roche
- Abbott Laboratories, Inc.
- Pfizer Inc.
- Sanofi S.A.
- Bayer AG
- Nestle Health Science
- Zydus Cadila
- Novartis AG
- Johnson & Johnson
- Merck Sharp & Dohme Corp.
- AstaReal AB
- AbbVie Inc.
- American Way (Amway) Corporation
Sarcopenia Market Growth & Trends
A key driver in the sarcopenia market is the increasing prevalence of age-related chronic conditions such as osteoporosis, frailty, and metabolic syndrome, which often co-occur with sarcopenia. This has led to a rising demand for combination therapies, including nutritional supplements and pharmaceutical agents that target both muscular and metabolic health.
Innovations in therapeutic approaches are also boosting growth. Research into myostatin inhibitors and hormonal therapies to reverse or prevent muscle wasting is gaining traction, with several drug candidates entering clinical trials.
Another growing trend is the development of personalized nutrition plans and digital platforms that monitor physical activity and muscle strength. Integration of wearable technology and AI for early detection of muscle degeneration is expected to become a standard component of sarcopenia management in the coming years.
Public health initiatives are also increasingly focused on prevention through physical rehabilitation programs, further stimulating demand for therapies that complement exercise-based interventions.
Sarcopenia Market Case Studies & News
Recent developments in the sarcopenia space highlight the dynamic nature of the market:
- Amgen and UCB have been advancing investigational therapies targeting myostatin, a protein that inhibits muscle growth. These drugs show promise in enhancing muscle mass in sarcopenic individuals.
- Nestlé Health Science has expanded its portfolio of clinical nutrition products specifically designed for elderly patients suffering from muscle wasting and mobility challenges.
- AstaReal AB has been focusing on astaxanthin-based antioxidant products that improve mitochondrial function in muscles, potentially aiding in sarcopenia prevention.
- Zydus Cadila launched a new oral supplement in India formulated with a mix of essential amino acids to combat early muscle degeneration among aging adults.
In Japan, where nearly 30% of the population is aged 65 or older, there have been strong public-private partnerships to address sarcopenia. The Japanese government has supported research on community-based rehabilitation and dietary interventions tailored to the elderly.
Sarcopenia Market Analysis
The sarcopenia market is moderately fragmented, with a mix of pharmaceutical giants, nutraceutical firms, and specialty nutrition companies competing in a landscape marked by rapid research evolution and increasing consumer awareness.
Regulatory environments vary widely. While the FDA and EMA have not yet approved specific drugs labeled solely for sarcopenia treatment, off-label use of certain medications and clinical nutrition protocols is common. However, increasing recognition of sarcopenia as a distinct medical condition could pave the way for specific regulatory approvals and reimbursement structures.
Regional insights suggest that:
- The United States is leading in clinical trials and research funding, supported by high healthcare spending and an aging baby boomer population.
- EU-4 and the United Kingdom have well-developed geriatric care systems, encouraging the adoption of hospital-based and homecare sarcopenia treatments.
- Japan, with its super-aged society, is pioneering preventive care models integrating diet, supplements, and functional rehabilitation.
- China is witnessing a sharp rise in aging demographics, prompting increased investments in healthcare infrastructure and elderly care services, boosting market potential.
Market Segmentation
By Treatment Type
- Protein Supplement
- Vitamin B12 Supplement
- Vitamin D & Calcium Supplement
- Pharmacotherapy
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
By Region
- United States
- EU-4 and the United Kingdom
- Japan
- China
The sarcopenia market is poised for steady growth, driven by aging demographics, expanding research horizons, and increasing public awareness of muscle health. Companies focusing on multi-modal therapies and personalized treatment strategies are expected to lead in this evolving landscape. For more in-depth market analysis, forecasts, and competitive data, consult detailed research from Expert Market Research.
Uncover More Reports
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
